Study of ABT-263 When Administered in Combination With Either Fludarabine/Cyclophosphamide/Rituximab or Bendamustine/Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia



Status:Archived
Conditions:Blood Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:November 2009

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1 Study Evaluating the Safety of ABT-263 in Combination With Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia


This is a Phase 1 study evaluating the safety of ABT-263 administered in combination with
either FCR or BR in subjects with relapsed or refractory chronic lymphocytic leukemia.



We found this trial at
7
sites
Hackensack Univeristy Medical Center
Hackensack, New Jersey 07601
?
mi
from
Hackensack, NJ
Click here to add this to my saved trials
Clinical Trial Facility in Baltimore Maryland
Baltimore, Maryland 21231
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clinical Trial Facility in Columbus Ohio
Columbus, Ohio 43210
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Clinical Trial Facility in Houston Texas
Houston, Texas 77030
?
mi
from
Houston, TX
Click here to add this to my saved trials
Clinical Trial Facility in La Jolla California
La Jolla, California 92093
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
Clinical Trial Facility in Philadephia Pennsylvania
Philadephia, Pennsylvania 19111
?
mi
from
Philadephia, PA
Click here to add this to my saved trials
Clinical Trial Facility in Stanford California
Stanford, California 94305
?
mi
from
Stanford, CA
Click here to add this to my saved trials